Table 1 Subject demographics.

From: Nationwide Glaucoma incidence in end stage renal disease patients and kidney transplant recipients

 

Healthy control (n = 10,955)

ESRD (n = 10,955)

KTR (n = 10,955)

P-value

Age, years (%)

45.8 ± 10.5

45.8 ± 10.5

45.8 ± 10.5

1a

20–29

782 (7.28)

782 (7.28)

782 (7.28)

 

30–39

2,294 (20.94)

2,294 (20.94)

2,294 (20.94)

 

40–49

3,529 (32.21)

3,529 (32.21)

3,529 (32.21)

 

50–59

3,303 (30.15)

3,303 (30.15)

3,303 (30.15)

 

60–69

981 (8.95)

981 (8.95)

981 (8.95)

 

 ≥ 70

50 (0.46)

50 (0.46)

50 (0.46)

 

Male sex, n (%)

6,484 (59.19)

6,484 (59.19)

6,484 (59.19)

1b

Diabetes mellitus, n (%)

692 (6.32)

4,416 (40.31)

4,416 (40.31)

 < 0.0001b

Hypertension, n (%)

1,796 (16.39)

10,003 (91.31)

10,003 (91.31)

 < 0.0001b

Dyslipidemia, n (%)

1,286 (11.74)

4,667 (42.6)

6,170 (56.32)

 < 0.0001b

Income, quartile, n (%)

   

 < 0.0001b

Aid

271 (2.47)

2,524 (23.04)

1,580 (14.42)

 

Q1

2,828 (25.81)

3,021(27.58)

2,203 (20.11)

 

Q2

2692 (24.57)

2,300 (20.99)

2,156 (19.68)

 

Q3

2,555 (23.32)

1,814 (16.56)

2,296 (20.96)

 

Q4

2,609 (23.82)

1,296 (11.83)

2,720 (24.83)

 

Dialysis modality, n (%)

   

 < 0.001b

No Dialysis History

10,955 (100)

0 (0)

3,487 (31.83)

 

Hemodialysis

0 (0)

8,119 (74.11)

4,890 (44.64)

 

Peritoneal dialysis

0 (0)

2,242 (20.47)

1,878 (17.14)

 

Mixed dialysis

0 (0)

594 (5.42)

700 (6.39)

 

Dialysis duration, years

0 ± 0

2.86 ± 3.03

2.82 ± 3.21

 < 0.0001c

 < 3 months

10,955 (100)

2,255 (20.58)

3,551 (32.41)

 < 0.0001b

3 months-1 year

0 (0)

1,831 (16.71)

1,384 (12.63)

 

1–2 years

0 (0)

1,706 (15.57)

1,014 (9.26)

 

2–3 years

0 (0)

1,150 (10.5)

811 (7.4)

 

3–4 years

0 (0)

864 (7.89)

690 (6.3)

 

4–5 years

0 (0)

690 (6.3)

762 (6.96)

 

 > 5 years

0 (0)

2,459 (22.45)

2,743 (25.04)

 

Induction medication, n (%)

   

 < 0.0001b

No use

10,955 (100)

10,955 (100)

574 (5.24)

 

Antithymocyte glubulin

0 (0)

0 (0)

920 (8.4)

 

Baxiliximab

0 (0)

0 (0)

9,461 (86.36)

 

Desensitization, n (%)

   

 < 0.0001b

No

10,955 (100)

10,955 (100)

9,252 (84.45)

 

Yes

0 (0)

0 (0)

1,703 (15.55)

 

CNI for maintenance therapy, n (%)

   

 < 0.0001b

None

10,955 (100)

10,955 (100)

263 (2.4)

 

Tacrolimus

0 (0)

0 (0)

8,937 (81.58)

 

Cyclosporin

0 (0)

0 (0)

1,755 (16.02)

 
  1. Mean ± standard deviation.
  2. ESRD end stage renal disease, KTR kidney transplantation recipients, CNI calcineurin inhibitor.
  3. aComparison was performed using ANOVA.
  4. bComparison was performed using chi-square test.
  5. cComparison was performed using the Kruskal–Wallis test due to absence of normality.
Back to article page